Tower Research Capital LLC TRC lifted its stake in Nu Skin Enterprises, Inc. (NYSE:NUS) by 28.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,909 shares of the company’s stock after acquiring an additional 1,305 shares during the period. Tower Research Capital LLC TRC’s holdings in Nu Skin Enterprises were worth $462,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NUS. Quantbot Technologies LP raised its position in shares of Nu Skin Enterprises by 293.0% in the 1st quarter. Quantbot Technologies LP now owns 2,071 shares of the company’s stock worth $152,000 after acquiring an additional 1,544 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Nu Skin Enterprises in the 2nd quarter worth $210,000. Greenleaf Trust bought a new position in shares of Nu Skin Enterprises in the 2nd quarter worth $216,000. Stevens Capital Management LP bought a new position in shares of Nu Skin Enterprises in the 2nd quarter worth $221,000. Finally, RBO & Co. LLC bought a new position in shares of Nu Skin Enterprises in the 2nd quarter worth $227,000. 76.00% of the stock is owned by hedge funds and other institutional investors.

In related news, President Ryan S. Napierski sold 10,000 shares of the company’s stock in a transaction dated Friday, August 3rd. The stock was sold at an average price of $80.00, for a total transaction of $800,000.00. Following the transaction, the president now directly owns 74,602 shares of the company’s stock, valued at approximately $5,968,160. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel D Matthew Dorny sold 3,500 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $77.65, for a total value of $271,775.00. The disclosure for this sale can be found here. Insiders have sold a total of 43,850 shares of company stock worth $3,589,888 over the last ninety days. 3.00% of the stock is currently owned by corporate insiders.

NUS has been the subject of several recent research reports. Zacks Investment Research raised Nu Skin Enterprises from a “sell” rating to a “hold” rating and set a $95.00 price target for the company in a research report on Monday, August 6th. Jefferies Financial Group initiated coverage on Nu Skin Enterprises in a research report on Thursday, June 14th. They issued a “buy” rating and a $98.00 price target for the company. ValuEngine lowered Nu Skin Enterprises from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 6th. Finally, Stifel Nicolaus raised Nu Skin Enterprises from a “sell” rating to a “hold” rating and upped their target price for the company from $57.00 to $70.00 in a research report on Thursday, August 2nd. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $85.33.

Shares of NYSE:NUS opened at $81.82 on Wednesday. Nu Skin Enterprises, Inc. has a 1 year low of $59.31 and a 1 year high of $88.68. The stock has a market cap of $4.69 billion, a P/E ratio of 26.02, a price-to-earnings-growth ratio of 2.41 and a beta of 1.11. The company has a current ratio of 1.82, a quick ratio of 1.19 and a debt-to-equity ratio of 0.46.

Nu Skin Enterprises (NYSE:NUS) last announced its earnings results on Thursday, August 2nd. The company reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.18. Nu Skin Enterprises had a return on equity of 25.67% and a net margin of 5.74%. The company had revenue of $704.19 million for the quarter, compared to analyst estimates of $642.16 million. During the same period in the prior year, the company posted $0.77 EPS. The firm’s quarterly revenue was up 28.0% compared to the same quarter last year. research analysts expect that Nu Skin Enterprises, Inc. will post 3.61 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 12th. Investors of record on Friday, August 31st were given a dividend of $0.365 per share. This represents a $1.46 annualized dividend and a yield of 1.78%. The ex-dividend date of this dividend was Thursday, August 30th. Nu Skin Enterprises’s dividend payout ratio is currently 45.20%.

Nu Skin Enterprises Company Profile

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.

Read More: Market Capitalization – What it Means for Investors

Institutional Ownership by Quarter for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.